U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07224321) titled 'INHALE-1st: Afrezza(R) For Youth With Newly-Diagnosed Type 1 Diabetes' on Oct. 31.
Brief Summary: INHALE-1st is a Phase 2, single-arm, multi-center, clinical study evaluating the safety and efficacy of Afrezza in combination with subcutaneously-injected basal insulin (BI) for youth 10 to <18 years old with newly diagnosed stage 3 type 1 diabetes (T1D). The study will also evaluate the effect of an Afrezza plus BI reigmen on participant and parent/legally authorized representative satisfaction. Participants will be followed for 13 weeks during the main phase followed by an optional Extension Phase for participants continuing to use Af...